Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed sentiment. Financial performance shows reduced losses and operational expenses, but revenue and cash reserves have significantly declined. Promising clinical results, especially in AFM24 and LuminICE-203, are offset by recruitment delays and competitive market risks. The Q&A highlights strong response rates but also reveals management's avoidance of specific timelines, raising uncertainty. No new partnerships or shareholder return changes were announced. Overall, the sentiment is balanced, suggesting a neutral stock price movement over the next two weeks.
Key Financial Performance
Cash, cash equivalents, and investments €48.5 million (decreased from €72 million on December 31, 2023) - The decrease is attributed to cash used in operating activities.
Net cash used in operating activities €23.8 million (decreased from €33.2 million for the quarter ended March 31, 2023) - The reduction indicates improved cash management or operational efficiency.
Total revenue €0.2 million (decreased from €4.5 million for the quarter ended March 31, 2023) - The decline in revenue may be due to fewer collaborations or product sales.
Net loss €19.2 million (decreased from a net loss of €32 million for the quarter ended March 31, 2023) - The reduction in net loss suggests improved cost management or operational efficiencies.
Operating Highlights
AFM24: Advancing combination study with atezolizumab in treatment refractory patients with non-small cell lung cancer, showing durable responses in patients with EGFR wild type tumors.
Acimtamig: Clinical LuminICE trial shows 85.7% overall response rate in patients with refractory Hodgkin's Lymphoma, including four complete remissions.
AFM28: CD123 targeting ICE for refractory AML shows clinical activity with complete responses in patients at dose levels 5 and 6.
Market Opportunity for AFM24: 175,000 patients with EGFR wild type and 35,000 with EGFR mutant non-small cell lung cancer annually in major markets.
Market Opportunity for AFM28: Over 14,000 patients per year in major markets who failed at least two lines of standard therapy for AML.
Patient Recruitment: Slight delay in recruitment for Acimtamig due to higher dropout rates, but improvement expected with additional active sites.
Strategic Reorganization: Focus on advancing clinical assets and leveraging innate immune system to fight cancer, with consistent activity signals across three programs.
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could lead to actual results differing materially from expectations. This includes regulatory challenges as indicated by the need for FDA agreement on trial designs.
Clinical Development Risks: There is a noted delay in patient recruitment for clinical trials, primarily due to a higher dropout rate during the screening period. This could impact timelines for data generation and overall project progress.
Financial Risks: Affimed's cash and cash equivalents decreased from €72 million to €48.5 million, raising concerns about liquidity and operational sustainability into the second half of 2025.
Market Competition Risks: The company faces competitive pressures in the oncology market, particularly in the treatment of refractory non-small cell lung cancer, where existing therapies have limited effectiveness.
Supply Chain Risks: The reliance on allogeneic NK cells for treatment development may pose supply chain challenges, particularly in ensuring consistent availability and quality of these cells for clinical trials.
Economic Factors: The overall economic environment may impact funding and investment in biotech, which could affect Affimed's ability to finance its operations and clinical programs.
Guidance & Outlook
Clinical Programs Validation: Affimed has achieved clinical validation for all three of its clinical programs, demonstrating consistent activity signals across different indications.
Focus on Innate Immune System: The company is strategically focused on leveraging the innate immune system to fight cancer, with promising data from AFM24, Acimtamig, and AFM28.
Patient Recruitment Improvement: Affimed expects to see further improvement in patient recruitment for its trials, despite a slight delay due to higher dropout rates.
Exploration of Allogeneic NK Cells: Affimed is actively exploring the continuation of the AFM28 program in combination with off-the-shelf allogeneic NK cells.
Liquidity Outlook: Affimed anticipates that its liquidity will support operations into the second half of 2025.
Future Data Readouts: The company guided that additional important data readouts will occur throughout the year.
Revenue Expectations: Total revenue for Q1 2024 was €0.2 million, a decrease from €4.5 million in Q1 2023.
Net Loss: Net loss for Q1 2024 was €19.2 million, compared to €32 million in Q1 2023.
Shareholder Return Plan
Shareholder Return Plan: Affimed has not announced any share buyback program or dividend program during this earnings call.
Key Q&A
Earnings Word Cloud
AFMD Transcript
The earnings call summary shows a decrease in revenue and cash position, despite reduced expenses and net loss. The Q&A section highlights uncertainties regarding AFM28's FDA path, collaboration strategies, and data maturity. These factors, combined with unclear management responses, suggest investor concerns. The lack of strong positive catalysts and the ongoing financial challenges lead to a negative sentiment, predicting a stock price decrease of -2% to -8%.
The earnings call reveals several negative aspects: declining revenue, significant cash burn, and lack of shareholder return plans. Operational and regulatory risks are highlighted, along with competitive pressures. Although there is optimism in clinical programs, management's vague responses in the Q&A section and the absence of new partnerships or positive guidance adjustments contribute to a negative outlook. The stock price is likely to fall between -2% to -8% due to these factors.
The earnings call reflects mixed sentiment. Financial performance shows reduced losses and operational expenses, but revenue and cash reserves have significantly declined. Promising clinical results, especially in AFM24 and LuminICE-203, are offset by recruitment delays and competitive market risks. The Q&A highlights strong response rates but also reveals management's avoidance of specific timelines, raising uncertainty. No new partnerships or shareholder return changes were announced. Overall, the sentiment is balanced, suggesting a neutral stock price movement over the next two weeks.
The earnings call revealed a sharp revenue decline, clinical trial recruitment challenges, and significant cash burn, with no clear guidance or new partnerships. Q&A highlighted uncertainties, such as management's avoidance of specifics and slower than expected trial enrollment. These factors, combined with competitive pressures and regulatory risks, suggest a strong negative sentiment, likely leading to a stock price decline.
AFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
